164 related articles for article (PubMed ID: 8535785)
1. The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: lessons for inhibitor design.
Ren J; Esnouf R; Hopkins A; Ross C; Jones Y; Stammers D; Stuart D
Structure; 1995 Sep; 3(9):915-26. PubMed ID: 8535785
[TBL] [Abstract][Full Text] [Related]
2. Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant.
Das K; Ding J; Hsiou Y; Clark AD; Moereels H; Koymans L; Andries K; Pauwels R; Janssen PA; Boyer PL; Clark P; Smith RH; Kroeger Smith MB; Michejda CJ; Hughes SH; Arnold E
J Mol Biol; 1996 Dec; 264(5):1085-100. PubMed ID: 9000632
[TBL] [Abstract][Full Text] [Related]
3. Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors.
Ding J; Das K; Moereels H; Koymans L; Andries K; Janssen PA; Hughes SH; Arnold E
Nat Struct Biol; 1995 May; 2(5):407-15. PubMed ID: 7545077
[TBL] [Abstract][Full Text] [Related]
4. Molecular modeling studies of HIV-1 reverse transcriptase nonnucleoside inhibitors: total energy of complexation as a predictor of drug placement and activity.
Kroeger Smith MB; Rouzer CA; Taneyhill LA; Smith NA; Hughes SH; Boyer PL; Janssen PA; Moereels H; Koymans L; Arnold E
Protein Sci; 1995 Oct; 4(10):2203-22. PubMed ID: 8535257
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors.
Esnouf R; Ren J; Ross C; Jones Y; Stammers D; Stuart D
Nat Struct Biol; 1995 Apr; 2(4):303-8. PubMed ID: 7540935
[TBL] [Abstract][Full Text] [Related]
6. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance.
Tantillo C; Ding J; Jacobo-Molina A; Nanni RG; Boyer PL; Hughes SH; Pauwels R; Andries K; Janssen PA; Arnold E
J Mol Biol; 1994 Oct; 243(3):369-87. PubMed ID: 7525966
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors.
Spence RA; Kati WM; Anderson KS; Johnson KA
Science; 1995 Feb; 267(5200):988-93. PubMed ID: 7532321
[TBL] [Abstract][Full Text] [Related]
8. High resolution structures of HIV-1 RT from four RT-inhibitor complexes.
Ren J; Esnouf R; Garman E; Somers D; Ross C; Kirby I; Keeling J; Darby G; Jones Y; Stuart D
Nat Struct Biol; 1995 Apr; 2(4):293-302. PubMed ID: 7540934
[TBL] [Abstract][Full Text] [Related]
9. Comparative molecular field analysis (CoMFA) and docking studies of non-nucleoside HIV-1 RT inhibitors (NNIs).
Barreca ML; Carotti A; Carrieri A; Chimirri A; Monforte AM; Calace MP; Rao A
Bioorg Med Chem; 1999 Nov; 7(11):2283-92. PubMed ID: 10632038
[TBL] [Abstract][Full Text] [Related]
10. Computational study of the interaction between TIBO inhibitors and Y181 (C181), K101, and Y188 amino acids.
Freitas RF; Galembeck SE
J Phys Chem B; 2006 Oct; 110(42):21287-98. PubMed ID: 17048958
[TBL] [Abstract][Full Text] [Related]
11. Molecular docking studies on tetrahydroimidazo-[4,5,1-jk][1,4]-benzodiazepinone (TIBO) derivatives as HIV-1 NNRT inhibitors.
Sapre NS; Gupta S; Pancholi N; Sapre N
J Comput Aided Mol Des; 2008 Feb; 22(2):69-80. PubMed ID: 18163186
[TBL] [Abstract][Full Text] [Related]
12. A single conservative amino acid substitution in the reverse transcriptase of human immunodeficiency virus-1 confers resistance to (+)-(5S)-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl)imidazo[4,5, 1- jk][1,4]benzodiazepin-2(1H)-thione (TIBO R82150).
Mellors JW; Im GJ; Tramontano E; Winkler SR; Medina DJ; Dutschman GE; Bazmi HZ; Piras G; Gonzalez CJ; Cheng YC
Mol Pharmacol; 1993 Jan; 43(1):11-6. PubMed ID: 7678690
[TBL] [Abstract][Full Text] [Related]
13. Enzymatic properties of two mutants of reverse transcriptase of human immunodeficiency virus type 1 (tyrosine 181-->isoleucine and tyrosine 188-->leucine), resistant to nonnucleoside inhibitors.
Loya S; Bakhanashvili M; Tal R; Hughes SH; Boyer PL; Hizi A
AIDS Res Hum Retroviruses; 1994 Aug; 10(8):939-46. PubMed ID: 7529032
[TBL] [Abstract][Full Text] [Related]
14. Treatment of human immunodeficiency virus type 1 (HIV-1)-infected cells with combinations of HIV-1-specific inhibitors results in a different resistance pattern than does treatment with single-drug therapy.
Balzarini J; Karlsson A; Pérez-Pérez MJ; Camarasa MJ; Tarpley WG; De Clercq E
J Virol; 1993 Sep; 67(9):5353-9. PubMed ID: 7688822
[TBL] [Abstract][Full Text] [Related]
15. Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor alpha-APA R 95845 at 2.8 A resolution.
Ding J; Das K; Tantillo C; Zhang W; Clark AD; Jessen S; Lu X; Hsiou Y; Jacobo-Molina A; Andries K
Structure; 1995 Apr; 3(4):365-79. PubMed ID: 7542140
[TBL] [Abstract][Full Text] [Related]
16. Kinetics of inhibition of endogenous human immunodeficiency virus type 1 reverse transcription by 2',3'-dideoxynucleoside 5'-triphosphate, tetrahydroimidazo-[4,5,1-jk][1,4]-benzodiazepin-2(1H)-thion e, and 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives.
Debyser Z; Vandamme AM; Pauwels R; Baba M; Desmyter J; De Clercq E
J Biol Chem; 1992 Jun; 267(17):11769-76. PubMed ID: 1376311
[TBL] [Abstract][Full Text] [Related]
17. Monte Carlo calculations on HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor 8-Cl TIBO: contribution of the L100I and Y181C variants to protein stability and biological activity.
Smith MB; Lamb ML; Tirado-Rives J; Jorgensen WL; Michejda CJ; Ruby SK; Smith RH
Protein Eng; 2000 Jun; 13(6):413-21. PubMed ID: 10877852
[TBL] [Abstract][Full Text] [Related]
18. Crystal structures of HIV-1 reverse transcriptase in complex with carboxanilide derivatives.
Ren J; Esnouf RM; Hopkins AL; Warren J; Balzarini J; Stuart DI; Stammers DK
Biochemistry; 1998 Oct; 37(41):14394-403. PubMed ID: 9772165
[TBL] [Abstract][Full Text] [Related]
19. Hologram quantitative structure-activity relationships investigations of non-nucleoside reverse transcriptase inhibitors.
Pungpo P; Hannongbua S; Wolschann P
Curr Med Chem; 2003 Sep; 10(17):1661-77. PubMed ID: 12871115
[TBL] [Abstract][Full Text] [Related]
20. Resistance of human immunodeficiency virus type 1 reverse transcriptase to TIBO derivatives induced by site-directed mutagenesis.
de Vreese K; Debyser Z; Vandamme AM; Pauwels R; Desmyter J; de Clercq E; Anné J
Virology; 1992 Jun; 188(2):900-4. PubMed ID: 1374986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
